Veracyte, Inc. and Gustave Roussy announced that they have entered into a collaboration to bring together their respective capabilities to provide novel insights into the underlying biology of metastatic tumors, which may help biopharmaceutical companies accelerate development of new cancer therapies. The multi-year partnership will leverage Gustave Roussy's expansive biorepository of tumor samples and associated data, as well as Veracyte's Biopharma Atlas, a machine learning-driven, multi-omic solution that is designed to increase the effectiveness and efficiency of clinical trials. Through the partnership, Gustave Roussy's Department of Therapeutic Innovation and Early Clinical Trials (DITEP) will provide metastatic tumor samples and data for multiple cancer indications that are derived from its major innovative research projects, particularly for new immunotherapies.

Veracyte will combine these assets with its multi-omics testing and machine learning capabilities to create a Veracyte Biopharma Atlas reference database of genetic and immunomic biomarkers. The company will then leverage this deep characterization of each tumor?s biology, particularly its immune contexture, to derive further insights about tumors that are more likely to respond to a particular therapy.